nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC6A2—locus ceruleus—Alzheimer's disease	0.0471	0.223	CbGeAlD
Lisdexamfetamine—SLC18A2—telencephalic ventricle—Alzheimer's disease	0.0366	0.173	CbGeAlD
Lisdexamfetamine—SLC6A3—telencephalic ventricle—Alzheimer's disease	0.0277	0.131	CbGeAlD
Lisdexamfetamine—Dysphoria—Donepezil—Alzheimer's disease	0.0128	0.0233	CcSEcCtD
Lisdexamfetamine—Sudden death—Memantine—Alzheimer's disease	0.00979	0.0179	CcSEcCtD
Lisdexamfetamine—SLC18A2—forebrain—Alzheimer's disease	0.00957	0.0453	CbGeAlD
Lisdexamfetamine—SLC18A2—telencephalon—Alzheimer's disease	0.0088	0.0416	CbGeAlD
Lisdexamfetamine—Aggression—Galantamine—Alzheimer's disease	0.0081	0.0148	CcSEcCtD
Lisdexamfetamine—SLC6A3—forebrain—Alzheimer's disease	0.00724	0.0342	CbGeAlD
Lisdexamfetamine—Mania—Memantine—Alzheimer's disease	0.00689	0.0126	CcSEcCtD
Lisdexamfetamine—SLC6A3—telencephalon—Alzheimer's disease	0.00665	0.0315	CbGeAlD
Lisdexamfetamine—Aggression—Donepezil—Alzheimer's disease	0.00628	0.0115	CcSEcCtD
Lisdexamfetamine—SLC6A2—forebrain—Alzheimer's disease	0.00584	0.0276	CbGeAlD
Lisdexamfetamine—Aggression—Memantine—Alzheimer's disease	0.0057	0.0104	CcSEcCtD
Lisdexamfetamine—Aggression—Rivastigmine—Alzheimer's disease	0.00558	0.0102	CcSEcCtD
Lisdexamfetamine—SLC6A2—telencephalon—Alzheimer's disease	0.00537	0.0254	CbGeAlD
Lisdexamfetamine—Dyskinesia—Memantine—Alzheimer's disease	0.00533	0.00972	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Galantamine—Alzheimer's disease	0.00527	0.00962	CcSEcCtD
Lisdexamfetamine—ADRA1B—nervous system—Alzheimer's disease	0.00524	0.0248	CbGeAlD
Lisdexamfetamine—Dyskinesia—Rivastigmine—Alzheimer's disease	0.00521	0.00951	CcSEcCtD
Lisdexamfetamine—SLC18A2—nervous system—Alzheimer's disease	0.00519	0.0246	CbGeAlD
Lisdexamfetamine—Disturbance in sexual arousal—Galantamine—Alzheimer's disease	0.00513	0.00935	CcSEcCtD
Lisdexamfetamine—ADRA1B—central nervous system—Alzheimer's disease	0.00505	0.0239	CbGeAlD
Lisdexamfetamine—SLC18A2—central nervous system—Alzheimer's disease	0.005	0.0237	CbGeAlD
Lisdexamfetamine—SLC18A2—cerebellum—Alzheimer's disease	0.00489	0.0231	CbGeAlD
Lisdexamfetamine—Euphoric mood—Donepezil—Alzheimer's disease	0.00474	0.00865	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Galantamine—Alzheimer's disease	0.00472	0.00861	CcSEcCtD
Lisdexamfetamine—Libido decreased—Donepezil—Alzheimer's disease	0.00432	0.00788	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Donepezil—Alzheimer's disease	0.00409	0.00745	CcSEcCtD
Lisdexamfetamine—Weight decreased—Galantamine—Alzheimer's disease	0.00404	0.00737	CcSEcCtD
Lisdexamfetamine—ADRA1B—brain—Alzheimer's disease	0.00401	0.019	CbGeAlD
Lisdexamfetamine—Disturbance in sexual arousal—Donepezil—Alzheimer's disease	0.00397	0.00725	CcSEcCtD
Lisdexamfetamine—Depression—Galantamine—Alzheimer's disease	0.00397	0.00724	CcSEcCtD
Lisdexamfetamine—SLC18A2—brain—Alzheimer's disease	0.00397	0.0188	CbGeAlD
Lisdexamfetamine—Affect lability—Donepezil—Alzheimer's disease	0.00394	0.00719	CcSEcCtD
Lisdexamfetamine—SLC6A3—nervous system—Alzheimer's disease	0.00393	0.0186	CbGeAlD
Lisdexamfetamine—Libido decreased—Memantine—Alzheimer's disease	0.00392	0.00715	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Donepezil—Alzheimer's disease	0.00391	0.00713	CcSEcCtD
Lisdexamfetamine—Libido decreased—Rivastigmine—Alzheimer's disease	0.00384	0.007	CcSEcCtD
Lisdexamfetamine—Irritability—Donepezil—Alzheimer's disease	0.00382	0.00697	CcSEcCtD
Lisdexamfetamine—SLC6A3—central nervous system—Alzheimer's disease	0.00378	0.0179	CbGeAlD
Lisdexamfetamine—Hepatobiliary disease—Galantamine—Alzheimer's disease	0.00377	0.00687	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Memantine—Alzheimer's disease	0.00371	0.00677	CcSEcCtD
Lisdexamfetamine—SLC6A3—cerebellum—Alzheimer's disease	0.0037	0.0175	CbGeAlD
Lisdexamfetamine—Abdominal pain upper—Donepezil—Alzheimer's disease	0.00366	0.00667	CcSEcCtD
Lisdexamfetamine—Diplopia—Memantine—Alzheimer's disease	0.00364	0.00663	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Rivastigmine—Alzheimer's disease	0.00363	0.00662	CcSEcCtD
Lisdexamfetamine—Disturbance in sexual arousal—Memantine—Alzheimer's disease	0.00361	0.00658	CcSEcCtD
Lisdexamfetamine—Affect lability—Memantine—Alzheimer's disease	0.00358	0.00653	CcSEcCtD
Lisdexamfetamine—Hepatitis—Galantamine—Alzheimer's disease	0.00357	0.00652	CcSEcCtD
Lisdexamfetamine—Diplopia—Rivastigmine—Alzheimer's disease	0.00356	0.00649	CcSEcCtD
Lisdexamfetamine—Hallucination—Galantamine—Alzheimer's disease	0.00356	0.00649	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Memantine—Alzheimer's disease	0.00355	0.00648	CcSEcCtD
Lisdexamfetamine—Disturbance in sexual arousal—Rivastigmine—Alzheimer's disease	0.00353	0.00644	CcSEcCtD
Lisdexamfetamine—Affect lability—Rivastigmine—Alzheimer's disease	0.0035	0.00639	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Rivastigmine—Alzheimer's disease	0.00347	0.00634	CcSEcCtD
Lisdexamfetamine—Irritability—Memantine—Alzheimer's disease	0.00347	0.00633	CcSEcCtD
Lisdexamfetamine—Visual impairment—Galantamine—Alzheimer's disease	0.00345	0.00628	CcSEcCtD
Lisdexamfetamine—Eye disorder—Galantamine—Alzheimer's disease	0.00334	0.00609	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Galantamine—Alzheimer's disease	0.00332	0.00605	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Rivastigmine—Alzheimer's disease	0.00325	0.00593	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Galantamine—Alzheimer's disease	0.00323	0.00589	CcSEcCtD
Lisdexamfetamine—SLC6A2—nervous system—Alzheimer's disease	0.00317	0.015	CbGeAlD
Lisdexamfetamine—Weight increased—Donepezil—Alzheimer's disease	0.00315	0.00575	CcSEcCtD
Lisdexamfetamine—Mental disorder—Galantamine—Alzheimer's disease	0.00313	0.00571	CcSEcCtD
Lisdexamfetamine—Weight decreased—Donepezil—Alzheimer's disease	0.00313	0.00571	CcSEcCtD
Lisdexamfetamine—Malnutrition—Galantamine—Alzheimer's disease	0.00311	0.00568	CcSEcCtD
Lisdexamfetamine—Depression—Donepezil—Alzheimer's disease	0.00308	0.00561	CcSEcCtD
Lisdexamfetamine—SLC6A2—central nervous system—Alzheimer's disease	0.00305	0.0144	CbGeAlD
Lisdexamfetamine—Acute coronary syndrome—Donepezil—Alzheimer's disease	0.00304	0.00555	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Donepezil—Alzheimer's disease	0.00303	0.00552	CcSEcCtD
Lisdexamfetamine—Nervousness—Galantamine—Alzheimer's disease	0.00302	0.00551	CcSEcCtD
Lisdexamfetamine—SLC6A3—brain—Alzheimer's disease	0.003	0.0142	CbGeAlD
Lisdexamfetamine—Vision blurred—Galantamine—Alzheimer's disease	0.00293	0.00535	CcSEcCtD
Lisdexamfetamine—Tremor—Galantamine—Alzheimer's disease	0.00292	0.00532	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Memantine—Alzheimer's disease	0.00289	0.00528	CcSEcCtD
Lisdexamfetamine—Weight increased—Memantine—Alzheimer's disease	0.00286	0.00522	CcSEcCtD
Lisdexamfetamine—Agitation—Galantamine—Alzheimer's disease	0.00286	0.00522	CcSEcCtD
Lisdexamfetamine—Weight decreased—Memantine—Alzheimer's disease	0.00284	0.00519	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Rivastigmine—Alzheimer's disease	0.00283	0.00517	CcSEcCtD
Lisdexamfetamine—Lacosamide—CA4—Alzheimer's disease	0.0028	0.166	CrCbGaD
Lisdexamfetamine—Weight increased—Rivastigmine—Alzheimer's disease	0.0028	0.0051	CcSEcCtD
Lisdexamfetamine—Depression—Memantine—Alzheimer's disease	0.00279	0.0051	CcSEcCtD
Lisdexamfetamine—Weight decreased—Rivastigmine—Alzheimer's disease	0.00278	0.00507	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Memantine—Alzheimer's disease	0.00278	0.00507	CcSEcCtD
Lisdexamfetamine—Hepatitis—Donepezil—Alzheimer's disease	0.00277	0.00505	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Memantine—Alzheimer's disease	0.00276	0.00504	CcSEcCtD
Lisdexamfetamine—Hallucination—Donepezil—Alzheimer's disease	0.00276	0.00503	CcSEcCtD
Lisdexamfetamine—Palpitations—Galantamine—Alzheimer's disease	0.00275	0.00502	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Memantine—Alzheimer's disease	0.00275	0.00501	CcSEcCtD
Lisdexamfetamine—Depression—Rivastigmine—Alzheimer's disease	0.00273	0.00499	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Rivastigmine—Alzheimer's disease	0.00272	0.00496	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Rivastigmine—Alzheimer's disease	0.0027	0.00493	CcSEcCtD
Lisdexamfetamine—Convulsion—Galantamine—Alzheimer's disease	0.0027	0.00492	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Rivastigmine—Alzheimer's disease	0.00269	0.0049	CcSEcCtD
Lisdexamfetamine—Hypertension—Galantamine—Alzheimer's disease	0.00269	0.0049	CcSEcCtD
Lisdexamfetamine—Visual impairment—Donepezil—Alzheimer's disease	0.00267	0.00487	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Memantine—Alzheimer's disease	0.00265	0.00483	CcSEcCtD
Lisdexamfetamine—Anxiety—Galantamine—Alzheimer's disease	0.00264	0.00482	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.00263	0.0048	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Rivastigmine—Alzheimer's disease	0.00259	0.00473	CcSEcCtD
Lisdexamfetamine—Dry mouth—Galantamine—Alzheimer's disease	0.00259	0.00473	CcSEcCtD
Lisdexamfetamine—Hepatitis—Memantine—Alzheimer's disease	0.00252	0.00459	CcSEcCtD
Lisdexamfetamine—Hallucination—Memantine—Alzheimer's disease	0.0025	0.00457	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Galantamine—Alzheimer's disease	0.00249	0.00454	CcSEcCtD
Lisdexamfetamine—Tachycardia—Galantamine—Alzheimer's disease	0.00248	0.00452	CcSEcCtD
Lisdexamfetamine—Skin disorder—Galantamine—Alzheimer's disease	0.00247	0.0045	CcSEcCtD
Lisdexamfetamine—Hepatitis—Rivastigmine—Alzheimer's disease	0.00246	0.00449	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Galantamine—Alzheimer's disease	0.00246	0.00448	CcSEcCtD
Lisdexamfetamine—Hallucination—Rivastigmine—Alzheimer's disease	0.00245	0.00447	CcSEcCtD
Lisdexamfetamine—Mental disorder—Donepezil—Alzheimer's disease	0.00243	0.00443	CcSEcCtD
Lisdexamfetamine—Visual impairment—Memantine—Alzheimer's disease	0.00242	0.00442	CcSEcCtD
Lisdexamfetamine—SLC6A2—brain—Alzheimer's disease	0.00242	0.0115	CbGeAlD
Lisdexamfetamine—Anorexia—Galantamine—Alzheimer's disease	0.00242	0.00442	CcSEcCtD
Lisdexamfetamine—Malnutrition—Donepezil—Alzheimer's disease	0.00241	0.0044	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Memantine—Alzheimer's disease	0.00238	0.00434	CcSEcCtD
Lisdexamfetamine—Visual impairment—Rivastigmine—Alzheimer's disease	0.00237	0.00433	CcSEcCtD
Lisdexamfetamine—Eye disorder—Memantine—Alzheimer's disease	0.00235	0.00429	CcSEcCtD
Lisdexamfetamine—Nervousness—Donepezil—Alzheimer's disease	0.00234	0.00427	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Memantine—Alzheimer's disease	0.00233	0.00426	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.00233	0.00424	CcSEcCtD
Lisdexamfetamine—Eye disorder—Rivastigmine—Alzheimer's disease	0.0023	0.0042	CcSEcCtD
Lisdexamfetamine—Insomnia—Galantamine—Alzheimer's disease	0.0023	0.00419	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.00228	0.00417	CcSEcCtD
Lisdexamfetamine—Vision blurred—Donepezil—Alzheimer's disease	0.00227	0.00415	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Memantine—Alzheimer's disease	0.00227	0.00414	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Memantine—Alzheimer's disease	0.00227	0.00414	CcSEcCtD
Lisdexamfetamine—Tremor—Donepezil—Alzheimer's disease	0.00226	0.00412	CcSEcCtD
Lisdexamfetamine—Somnolence—Galantamine—Alzheimer's disease	0.00226	0.00412	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Galantamine—Alzheimer's disease	0.00224	0.00408	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.00222	0.00405	CcSEcCtD
Lisdexamfetamine—Agitation—Donepezil—Alzheimer's disease	0.00222	0.00404	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Galantamine—Alzheimer's disease	0.00221	0.00403	CcSEcCtD
Lisdexamfetamine—Mental disorder—Memantine—Alzheimer's disease	0.0022	0.00402	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.00219	0.004	CcSEcCtD
Lisdexamfetamine—Malnutrition—Memantine—Alzheimer's disease	0.00219	0.00399	CcSEcCtD
Lisdexamfetamine—Fatigue—Galantamine—Alzheimer's disease	0.00219	0.00399	CcSEcCtD
Lisdexamfetamine—Constipation—Galantamine—Alzheimer's disease	0.00217	0.00396	CcSEcCtD
Lisdexamfetamine—Mental disorder—Rivastigmine—Alzheimer's disease	0.00216	0.00393	CcSEcCtD
Lisdexamfetamine—Malnutrition—Rivastigmine—Alzheimer's disease	0.00214	0.00391	CcSEcCtD
Lisdexamfetamine—Lisinopril—ACE—Alzheimer's disease	0.00214	0.126	CrCbGaD
Lisdexamfetamine—Nervousness—Memantine—Alzheimer's disease	0.00213	0.00388	CcSEcCtD
Lisdexamfetamine—Convulsion—Donepezil—Alzheimer's disease	0.00209	0.00381	CcSEcCtD
Lisdexamfetamine—Hypertension—Donepezil—Alzheimer's disease	0.00208	0.0038	CcSEcCtD
Lisdexamfetamine—Nervousness—Rivastigmine—Alzheimer's disease	0.00208	0.0038	CcSEcCtD
Lisdexamfetamine—Vision blurred—Memantine—Alzheimer's disease	0.00206	0.00376	CcSEcCtD
Lisdexamfetamine—Selegiline—MAOB—Alzheimer's disease	0.00206	0.122	CrCbGaD
Lisdexamfetamine—Tremor—Memantine—Alzheimer's disease	0.00205	0.00374	CcSEcCtD
Lisdexamfetamine—Anxiety—Donepezil—Alzheimer's disease	0.00205	0.00373	CcSEcCtD
Lisdexamfetamine—Vision blurred—Rivastigmine—Alzheimer's disease	0.00202	0.00368	CcSEcCtD
Lisdexamfetamine—Agitation—Memantine—Alzheimer's disease	0.00201	0.00367	CcSEcCtD
Lisdexamfetamine—Dry mouth—Donepezil—Alzheimer's disease	0.00201	0.00366	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Galantamine—Alzheimer's disease	0.00201	0.00366	CcSEcCtD
Lisdexamfetamine—Tremor—Rivastigmine—Alzheimer's disease	0.00201	0.00366	CcSEcCtD
Lisdexamfetamine—Agitation—Rivastigmine—Alzheimer's disease	0.00197	0.00359	CcSEcCtD
Lisdexamfetamine—Palpitations—Memantine—Alzheimer's disease	0.00194	0.00353	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Donepezil—Alzheimer's disease	0.00193	0.00352	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Donepezil—Alzheimer's disease	0.0019	0.00347	CcSEcCtD
Lisdexamfetamine—Convulsion—Memantine—Alzheimer's disease	0.0019	0.00346	CcSEcCtD
Lisdexamfetamine—Palpitations—Rivastigmine—Alzheimer's disease	0.00189	0.00345	CcSEcCtD
Lisdexamfetamine—Hypertension—Memantine—Alzheimer's disease	0.00189	0.00345	CcSEcCtD
Lisdexamfetamine—Anorexia—Donepezil—Alzheimer's disease	0.00188	0.00342	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Galantamine—Alzheimer's disease	0.00187	0.00341	CcSEcCtD
Lisdexamfetamine—Anxiety—Memantine—Alzheimer's disease	0.00186	0.00339	CcSEcCtD
Lisdexamfetamine—Convulsion—Rivastigmine—Alzheimer's disease	0.00186	0.00339	CcSEcCtD
Lisdexamfetamine—Hypertension—Rivastigmine—Alzheimer's disease	0.00185	0.00337	CcSEcCtD
Lisdexamfetamine—Dry mouth—Memantine—Alzheimer's disease	0.00182	0.00333	CcSEcCtD
Lisdexamfetamine—Asthenia—Galantamine—Alzheimer's disease	0.00182	0.00332	CcSEcCtD
Lisdexamfetamine—Phenelzine—MAOB—Alzheimer's disease	0.00182	0.108	CrCbGaD
Lisdexamfetamine—Anxiety—Rivastigmine—Alzheimer's disease	0.00182	0.00332	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.00181	0.0033	CcSEcCtD
Lisdexamfetamine—Dry mouth—Rivastigmine—Alzheimer's disease	0.00178	0.00325	CcSEcCtD
Lisdexamfetamine—Insomnia—Donepezil—Alzheimer's disease	0.00178	0.00325	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Donepezil—Alzheimer's disease	0.00175	0.0032	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Memantine—Alzheimer's disease	0.00175	0.0032	CcSEcCtD
Lisdexamfetamine—Somnolence—Donepezil—Alzheimer's disease	0.00175	0.00319	CcSEcCtD
Lisdexamfetamine—Tachycardia—Memantine—Alzheimer's disease	0.00174	0.00318	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Galantamine—Alzheimer's disease	0.00174	0.00317	CcSEcCtD
Lisdexamfetamine—Skin disorder—Memantine—Alzheimer's disease	0.00174	0.00317	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Donepezil—Alzheimer's disease	0.00173	0.00316	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Memantine—Alzheimer's disease	0.00173	0.00315	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.00171	0.00313	CcSEcCtD
Lisdexamfetamine—Amphetamine—MAOB—Alzheimer's disease	0.00171	0.101	CrCbGaD
Lisdexamfetamine—Decreased appetite—Donepezil—Alzheimer's disease	0.00171	0.00312	CcSEcCtD
Lisdexamfetamine—Tachycardia—Rivastigmine—Alzheimer's disease	0.00171	0.00311	CcSEcCtD
Lisdexamfetamine—Anorexia—Memantine—Alzheimer's disease	0.0017	0.00311	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.0017	0.0031	CcSEcCtD
Lisdexamfetamine—Skin disorder—Rivastigmine—Alzheimer's disease	0.0017	0.0031	CcSEcCtD
Lisdexamfetamine—Fatigue—Donepezil—Alzheimer's disease	0.0017	0.0031	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.00169	0.00308	CcSEcCtD
Lisdexamfetamine—Constipation—Donepezil—Alzheimer's disease	0.00168	0.00307	CcSEcCtD
Lisdexamfetamine—Dizziness—Galantamine—Alzheimer's disease	0.00168	0.00306	CcSEcCtD
Lisdexamfetamine—Anorexia—Rivastigmine—Alzheimer's disease	0.00167	0.00304	CcSEcCtD
Lisdexamfetamine—Insomnia—Memantine—Alzheimer's disease	0.00162	0.00295	CcSEcCtD
Lisdexamfetamine—Vomiting—Galantamine—Alzheimer's disease	0.00161	0.00295	CcSEcCtD
Lisdexamfetamine—Rash—Galantamine—Alzheimer's disease	0.0016	0.00292	CcSEcCtD
Lisdexamfetamine—Dermatitis—Galantamine—Alzheimer's disease	0.0016	0.00292	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Memantine—Alzheimer's disease	0.00159	0.00291	CcSEcCtD
Lisdexamfetamine—Headache—Galantamine—Alzheimer's disease	0.00159	0.0029	CcSEcCtD
Lisdexamfetamine—Somnolence—Memantine—Alzheimer's disease	0.00159	0.0029	CcSEcCtD
Lisdexamfetamine—Methamphetamine—MAOB—Alzheimer's disease	0.00159	0.094	CrCbGaD
Lisdexamfetamine—Insomnia—Rivastigmine—Alzheimer's disease	0.00158	0.00288	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Memantine—Alzheimer's disease	0.00157	0.00287	CcSEcCtD
Lisdexamfetamine—Urticaria—Donepezil—Alzheimer's disease	0.00156	0.00285	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Rivastigmine—Alzheimer's disease	0.00156	0.00284	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Donepezil—Alzheimer's disease	0.00156	0.00284	CcSEcCtD
Lisdexamfetamine—Somnolence—Rivastigmine—Alzheimer's disease	0.00155	0.00284	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Memantine—Alzheimer's disease	0.00155	0.00283	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.00154	0.00281	CcSEcCtD
Lisdexamfetamine—Fatigue—Memantine—Alzheimer's disease	0.00154	0.00281	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Rivastigmine—Alzheimer's disease	0.00154	0.00281	CcSEcCtD
Lisdexamfetamine—Constipation—Memantine—Alzheimer's disease	0.00153	0.00279	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Rivastigmine—Alzheimer's disease	0.00152	0.00277	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.00151	0.00275	CcSEcCtD
Lisdexamfetamine—Nausea—Galantamine—Alzheimer's disease	0.00151	0.00275	CcSEcCtD
Lisdexamfetamine—Fatigue—Rivastigmine—Alzheimer's disease	0.00151	0.00275	CcSEcCtD
Lisdexamfetamine—Constipation—Rivastigmine—Alzheimer's disease	0.0015	0.00273	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Donepezil—Alzheimer's disease	0.00145	0.00265	CcSEcCtD
Lisdexamfetamine—Urticaria—Memantine—Alzheimer's disease	0.00142	0.00259	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Memantine—Alzheimer's disease	0.00141	0.00258	CcSEcCtD
Lisdexamfetamine—Asthenia—Donepezil—Alzheimer's disease	0.00141	0.00258	CcSEcCtD
Lisdexamfetamine—Urticaria—Rivastigmine—Alzheimer's disease	0.00139	0.00253	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Rivastigmine—Alzheimer's disease	0.00138	0.00252	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Donepezil—Alzheimer's disease	0.00135	0.00246	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Memantine—Alzheimer's disease	0.00132	0.0024	CcSEcCtD
Lisdexamfetamine—Dizziness—Donepezil—Alzheimer's disease	0.0013	0.00237	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCA7—Alzheimer's disease	0.00129	0.00577	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.00129	0.00235	CcSEcCtD
Lisdexamfetamine—Asthenia—Memantine—Alzheimer's disease	0.00128	0.00234	CcSEcCtD
Lisdexamfetamine—Asthenia—Rivastigmine—Alzheimer's disease	0.00125	0.00229	CcSEcCtD
Lisdexamfetamine—Vomiting—Donepezil—Alzheimer's disease	0.00125	0.00228	CcSEcCtD
Lisdexamfetamine—Rash—Donepezil—Alzheimer's disease	0.00124	0.00226	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—Alzheimer's disease	0.00124	0.00555	CbGpPWpGaD
Lisdexamfetamine—Dermatitis—Donepezil—Alzheimer's disease	0.00124	0.00226	CcSEcCtD
Lisdexamfetamine—Headache—Donepezil—Alzheimer's disease	0.00123	0.00225	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Memantine—Alzheimer's disease	0.00122	0.00223	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Rivastigmine—Alzheimer's disease	0.0012	0.00218	CcSEcCtD
Lisdexamfetamine—Dizziness—Memantine—Alzheimer's disease	0.00118	0.00216	CcSEcCtD
Lisdexamfetamine—Nausea—Donepezil—Alzheimer's disease	0.00117	0.00213	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CHAT—Alzheimer's disease	0.00116	0.00519	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—GRIK2—Alzheimer's disease	0.00116	0.00519	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Rivastigmine—Alzheimer's disease	0.00116	0.00211	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—SLC18A3—Alzheimer's disease	0.00115	0.00516	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC24A4—Alzheimer's disease	0.00115	0.00514	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Memantine—Alzheimer's disease	0.00114	0.00207	CcSEcCtD
Lisdexamfetamine—Rash—Memantine—Alzheimer's disease	0.00113	0.00206	CcSEcCtD
Lisdexamfetamine—Dermatitis—Memantine—Alzheimer's disease	0.00113	0.00205	CcSEcCtD
Lisdexamfetamine—Headache—Memantine—Alzheimer's disease	0.00112	0.00204	CcSEcCtD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR2A—Alzheimer's disease	0.00111	0.00497	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Rivastigmine—Alzheimer's disease	0.00111	0.00203	CcSEcCtD
Lisdexamfetamine—Rash—Rivastigmine—Alzheimer's disease	0.0011	0.00201	CcSEcCtD
Lisdexamfetamine—Dermatitis—Rivastigmine—Alzheimer's disease	0.0011	0.00201	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—Alzheimer's disease	0.0011	0.00492	CbGpPWpGaD
Lisdexamfetamine—Headache—Rivastigmine—Alzheimer's disease	0.0011	0.002	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—PTK2B—Alzheimer's disease	0.00107	0.00477	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—TGFB1—Alzheimer's disease	0.00106	0.00476	CbGpPWpGaD
Lisdexamfetamine—Nausea—Memantine—Alzheimer's disease	0.00106	0.00194	CcSEcCtD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC30A6—Alzheimer's disease	0.00106	0.00472	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CHRNA7—Alzheimer's disease	0.00104	0.00467	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—GRIK1—Alzheimer's disease	0.00104	0.00467	CbGpPWpGaD
Lisdexamfetamine—Nausea—Rivastigmine—Alzheimer's disease	0.00104	0.00189	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—GRIA1—Alzheimer's disease	0.00103	0.00462	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CHRNB2—Alzheimer's disease	0.000978	0.00438	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC30A6—Alzheimer's disease	0.000935	0.00418	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR2A—Alzheimer's disease	0.000935	0.00418	CbGpPWpGaD
Lisdexamfetamine—Labetalol—CYP2D6—Alzheimer's disease	0.000901	0.0533	CrCbGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—ACHE—Alzheimer's disease	0.000899	0.00402	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PLCB1—Alzheimer's disease	0.000899	0.00402	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—APOD—Alzheimer's disease	0.000898	0.00401	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA4—Alzheimer's disease	0.000888	0.00397	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CHAT—Alzheimer's disease	0.000888	0.00397	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—GRIK2—Alzheimer's disease	0.000888	0.00397	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—SLC18A3—Alzheimer's disease	0.000884	0.00395	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—IL1B—Alzheimer's disease	0.000875	0.00392	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCA7—Alzheimer's disease	0.000868	0.00388	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—YWHAQ—Alzheimer's disease	0.000868	0.00388	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—CP—Alzheimer's disease	0.000838	0.00375	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA7—Alzheimer's disease	0.000813	0.00364	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—GRIK1—Alzheimer's disease	0.000813	0.00364	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC30A6—Alzheimer's disease	0.000797	0.00357	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—APOD—Alzheimer's disease	0.000795	0.00356	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—GRIA1—Alzheimer's disease	0.000792	0.00354	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—BCHE—Alzheimer's disease	0.000783	0.0035	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—IL1B—Alzheimer's disease	0.000776	0.00347	CbGpPWpGaD
Lisdexamfetamine—Amphetamine—SLC6A4—Alzheimer's disease	0.000775	0.0459	CrCbGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC24A4—Alzheimer's disease	0.000774	0.00346	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCA7—Alzheimer's disease	0.000769	0.00344	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—DLG4—Alzheimer's disease	0.000764	0.00342	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CHRNB2—Alzheimer's disease	0.00075	0.00335	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—GRIN2B—Alzheimer's disease	0.000747	0.00334	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—PLCB1—Alzheimer's disease	0.000739	0.00331	CbGpPWpGaD
Lisdexamfetamine—Methamphetamine—SLC6A4—Alzheimer's disease	0.000718	0.0425	CrCbGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A4—Alzheimer's disease	0.000715	0.0032	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CHAT—Alzheimer's disease	0.000691	0.00309	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—GRIK2—Alzheimer's disease	0.000691	0.00309	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—ACHE—Alzheimer's disease	0.000689	0.00308	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC24A4—Alzheimer's disease	0.000686	0.00307	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CHRNA4—Alzheimer's disease	0.000681	0.00305	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—APOD—Alzheimer's disease	0.000678	0.00303	CbGpPWpGaD
Lisdexamfetamine—Dextroamphetamine—CYP2D6—Alzheimer's disease	0.000676	0.04	CrCbGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—Alzheimer's disease	0.000674	0.00302	CbGpPWpGaD
Lisdexamfetamine—Selegiline—CYP2D6—Alzheimer's disease	0.000655	0.0388	CrCbGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TNF—Alzheimer's disease	0.000635	0.00284	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—Alzheimer's disease	0.000635	0.00284	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC6A4—Alzheimer's disease	0.000633	0.00283	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CHRNA7—Alzheimer's disease	0.000623	0.00279	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—GRIK1—Alzheimer's disease	0.000623	0.00279	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—GRIA1—Alzheimer's disease	0.000616	0.00276	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PYY—Alzheimer's disease	0.000614	0.00275	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—BCHE—Alzheimer's disease	0.0006	0.00268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR6—Alzheimer's disease	0.000598	0.00267	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—DLG4—Alzheimer's disease	0.000586	0.00262	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CHRNB2—Alzheimer's disease	0.000583	0.00261	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—LEP—Alzheimer's disease	0.000573	0.00256	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—GRIN2B—Alzheimer's disease	0.000572	0.00256	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—PLCB1—Alzheimer's disease	0.000566	0.00253	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—CP—Alzheimer's disease	0.000564	0.00252	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TNF—Alzheimer's disease	0.000563	0.00252	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—PRKCG—Alzheimer's disease	0.000546	0.00244	CbGpPWpGaD
Lisdexamfetamine—Amphetamine—CYP2D6—Alzheimer's disease	0.000545	0.0322	CrCbGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC30A6—Alzheimer's disease	0.000536	0.0024	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—ACHE—Alzheimer's disease	0.000536	0.0024	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—HMOX1—Alzheimer's disease	0.000532	0.00238	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—Alzheimer's disease	0.00053	0.00237	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CHAT—Alzheimer's disease	0.000529	0.00237	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—GRIK2—Alzheimer's disease	0.000529	0.00237	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—GSK3B—Alzheimer's disease	0.000527	0.00236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR6—Alzheimer's disease	0.000512	0.00229	CbGpPWpGaD
Lisdexamfetamine—Methamphetamine—CYP2D6—Alzheimer's disease	0.000505	0.0299	CrCbGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—CP—Alzheimer's disease	0.000499	0.00223	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—AGER—Alzheimer's disease	0.000478	0.00214	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC30A6—Alzheimer's disease	0.000475	0.00213	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CALM1—Alzheimer's disease	0.000473	0.00211	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—GRIA1—Alzheimer's disease	0.000472	0.00211	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—HMOX1—Alzheimer's disease	0.000471	0.00211	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PYY—Alzheimer's disease	0.000467	0.00209	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—BCHE—Alzheimer's disease	0.000467	0.00209	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—NPS—Alzheimer's disease	0.000461	0.00206	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—APOD—Alzheimer's disease	0.000456	0.00204	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—DLG4—Alzheimer's disease	0.000456	0.00204	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CHRNB2—Alzheimer's disease	0.000447	0.002	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—GRIN2B—Alzheimer's disease	0.000445	0.00199	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—PLCB1—Alzheimer's disease	0.00044	0.00197	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—APP—Alzheimer's disease	0.000429	0.00192	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—CP—Alzheimer's disease	0.000426	0.0019	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—GAL—Alzheimer's disease	0.000425	0.0019	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—AGER—Alzheimer's disease	0.000423	0.00189	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—PRKCG—Alzheimer's disease	0.000419	0.00187	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—Alzheimer's disease	0.000413	0.00185	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—ACHE—Alzheimer's disease	0.000411	0.00184	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CHRNA4—Alzheimer's disease	0.000406	0.00182	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PLCB1—Alzheimer's disease	0.000405	0.00181	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CREB1—Alzheimer's disease	0.000405	0.00181	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—APOD—Alzheimer's disease	0.000404	0.00181	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR6—Alzheimer's disease	0.00039	0.00174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CASP3—Alzheimer's disease	0.000387	0.00173	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—APP—Alzheimer's disease	0.000384	0.00172	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CALM1—Alzheimer's disease	0.000362	0.00162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB1—Alzheimer's disease	0.000362	0.00162	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—TF—Alzheimer's disease	0.000362	0.00162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—PRKCG—Alzheimer's disease	0.000359	0.00161	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BCHE—Alzheimer's disease	0.000358	0.0016	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—DLG4—Alzheimer's disease	0.000349	0.00156	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—GRIN2B—Alzheimer's disease	0.000341	0.00153	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—PLCB1—Alzheimer's disease	0.000337	0.00151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—NPY—Alzheimer's disease	0.000334	0.00149	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—PRKCG—Alzheimer's disease	0.000326	0.00146	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GAL—Alzheimer's disease	0.000324	0.00145	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—CALM1—Alzheimer's disease	0.000311	0.00139	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CREB1—Alzheimer's disease	0.00031	0.00139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—NPS—Alzheimer's disease	0.000306	0.00137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—SST—Alzheimer's disease	0.000292	0.0013	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—CP—Alzheimer's disease	0.000286	0.00128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—APP—Alzheimer's disease	0.000284	0.00127	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CALM1—Alzheimer's disease	0.000282	0.00126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HTR2A—Alzheimer's disease	0.000278	0.00124	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PYY—Alzheimer's disease	0.000264	0.00118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—NPY—Alzheimer's disease	0.000254	0.00114	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—CP—Alzheimer's disease	0.000254	0.00113	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—Alzheimer's disease	0.000253	0.00113	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—IAPP—Alzheimer's disease	0.000253	0.00113	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—PRKCG—Alzheimer's disease	0.00025	0.00112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Alzheimer's disease	0.000248	0.00111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CRH—Alzheimer's disease	0.000246	0.0011	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TF—Alzheimer's disease	0.000244	0.00109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—F2—Alzheimer's disease	0.000243	0.00109	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CREB1—Alzheimer's disease	0.000241	0.00108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PYY—Alzheimer's disease	0.00024	0.00107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—Alzheimer's disease	0.000234	0.00105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—NPS—Alzheimer's disease	0.000233	0.00104	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SST—Alzheimer's disease	0.000222	0.000993	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR6—Alzheimer's disease	0.00022	0.000986	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR5—Alzheimer's disease	0.000219	0.000981	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—F2—Alzheimer's disease	0.000218	0.000974	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—APP—Alzheimer's disease	0.000216	0.000968	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CALM1—Alzheimer's disease	0.000216	0.000966	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TF—Alzheimer's disease	0.000216	0.000965	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—Alzheimer's disease	0.000215	0.00096	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—Alzheimer's disease	0.00021	0.000937	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CDK5—Alzheimer's disease	0.000208	0.00093	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—Alzheimer's disease	0.000202	0.000904	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR6—Alzheimer's disease	0.0002	0.000895	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CREB1—Alzheimer's disease	0.000198	0.000887	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—Alzheimer's disease	0.000197	0.000883	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR5—Alzheimer's disease	0.000188	0.00084	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CREB1—Alzheimer's disease	0.000185	0.000827	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Alzheimer's disease	0.000184	0.000822	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GAL—Alzheimer's disease	0.000183	0.000819	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—Alzheimer's disease	0.000179	0.0008	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—Alzheimer's disease	0.00017	0.000762	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GAL—Alzheimer's disease	0.000166	0.000744	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TTR—Alzheimer's disease	0.000162	0.000725	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—F2—Alzheimer's disease	0.000161	0.000721	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—Alzheimer's disease	0.000151	0.000675	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPY—Alzheimer's disease	0.000144	0.000643	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—Alzheimer's disease	0.000144	0.000643	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCR5—Alzheimer's disease	0.000143	0.00064	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IAPP—Alzheimer's disease	0.000143	0.000639	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PYY—Alzheimer's disease	0.000142	0.000634	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2A—Alzheimer's disease	0.00014	0.000626	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CRH—Alzheimer's disease	0.000139	0.000621	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPS—Alzheimer's disease	0.000132	0.000588	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPY—Alzheimer's disease	0.000131	0.000584	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IAPP—Alzheimer's disease	0.00013	0.000581	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CRH—Alzheimer's disease	0.000126	0.000564	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SST—Alzheimer's disease	0.000125	0.000561	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GAB2—Alzheimer's disease	0.000125	0.000561	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDK5—Alzheimer's disease	0.000123	0.00055	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—F2—Alzheimer's disease	0.000123	0.000549	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—APP—Alzheimer's disease	0.000122	0.000547	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPS—Alzheimer's disease	0.000119	0.000534	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PPP3CA—Alzheimer's disease	0.000119	0.000532	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR6—Alzheimer's disease	0.000118	0.000529	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PLCB1—Alzheimer's disease	0.000115	0.000516	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GAB2—Alzheimer's disease	0.000114	0.00051	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SST—Alzheimer's disease	0.000114	0.00051	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—APP—Alzheimer's disease	0.000111	0.000497	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCL2—Alzheimer's disease	0.000109	0.000489	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PSENEN—Alzheimer's disease	0.000107	0.00048	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APH1A—Alzheimer's disease	0.000106	0.000474	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PLCB1—Alzheimer's disease	0.000105	0.000469	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NCSTN—Alzheimer's disease	0.000103	0.000461	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LRP1—Alzheimer's disease	0.000101	0.00045	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GFAP—Alzheimer's disease	9.82e-05	0.000439	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GAL—Alzheimer's disease	9.82e-05	0.000439	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—A2M—Alzheimer's disease	8.66e-05	0.000387	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Alzheimer's disease	8.62e-05	0.000385	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCG—Alzheimer's disease	8.53e-05	0.000382	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PSEN2—Alzheimer's disease	8.38e-05	0.000375	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR5—Alzheimer's disease	8.09e-05	0.000362	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2A—Alzheimer's disease	7.91e-05	0.000354	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCG—Alzheimer's disease	7.75e-05	0.000347	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPY—Alzheimer's disease	7.71e-05	0.000345	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IAPP—Alzheimer's disease	7.67e-05	0.000343	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CRH—Alzheimer's disease	7.44e-05	0.000333	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR5—Alzheimer's disease	7.34e-05	0.000328	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2A—Alzheimer's disease	7.19e-05	0.000321	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPS—Alzheimer's disease	7.06e-05	0.000316	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPP3CA—Alzheimer's disease	7.02e-05	0.000314	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—F2—Alzheimer's disease	6.94e-05	0.00031	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTK2B—Alzheimer's disease	6.92e-05	0.00031	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GAB2—Alzheimer's disease	6.73e-05	0.000301	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTRK2—Alzheimer's disease	6.73e-05	0.000301	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SST—Alzheimer's disease	6.73e-05	0.000301	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CALM1—Alzheimer's disease	6.7e-05	0.0003	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GSK3A—Alzheimer's disease	6.67e-05	0.000298	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APP—Alzheimer's disease	6.56e-05	0.000293	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—F2—Alzheimer's disease	6.3e-05	0.000282	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLCB1—Alzheimer's disease	6.19e-05	0.000277	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NGFR—Alzheimer's disease	5.77e-05	0.000258	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CREB1—Alzheimer's disease	5.74e-05	0.000257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADAM10—Alzheimer's disease	5.64e-05	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCL2—Alzheimer's disease	5.61e-05	0.000251	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—S100B—Alzheimer's disease	5.33e-05	0.000239	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF2—Alzheimer's disease	5.08e-05	0.000227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1R—Alzheimer's disease	4.91e-05	0.00022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LPL—Alzheimer's disease	4.71e-05	0.000211	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MEF2C—Alzheimer's disease	4.67e-05	0.000209	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCG—Alzheimer's disease	4.58e-05	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NGF—Alzheimer's disease	4.46e-05	0.000199	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR5—Alzheimer's disease	4.34e-05	0.000194	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2A—Alzheimer's disease	4.24e-05	0.00019	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CALM1—Alzheimer's disease	3.96e-05	0.000177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEP—Alzheimer's disease	3.95e-05	0.000177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOE—Alzheimer's disease	3.95e-05	0.000177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CAV1—Alzheimer's disease	3.91e-05	0.000175	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ESR1—Alzheimer's disease	3.77e-05	0.000169	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—F2—Alzheimer's disease	3.72e-05	0.000166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH1—Alzheimer's disease	3.64e-05	0.000163	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GSK3B—Alzheimer's disease	3.42e-05	0.000153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CREB1—Alzheimer's disease	3.39e-05	0.000152	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—INS—Alzheimer's disease	3.37e-05	0.000151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCL2—Alzheimer's disease	3.32e-05	0.000148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1—Alzheimer's disease	3.26e-05	0.000146	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOS3—Alzheimer's disease	2.96e-05	0.000132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—Alzheimer's disease	2.53e-05	0.000113	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—Alzheimer's disease	2.51e-05	0.000112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—Alzheimer's disease	2.49e-05	0.000112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK8—Alzheimer's disease	2.31e-05	0.000103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—Alzheimer's disease	2.3e-05	0.000103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—Alzheimer's disease	2.13e-05	9.53e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—Alzheimer's disease	1.95e-05	8.74e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—Alzheimer's disease	1.61e-05	7.2e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—Alzheimer's disease	1.47e-05	6.59e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—Alzheimer's disease	1.36e-05	6.08e-05	CbGpPWpGaD
